چكيده فارسي :
Over the years, peptides have been evolved as promising therapeutic agents in the
treatment of cancer, diabetes, and cardiovascular diseases, and application of peptides in a
variety of other therapeutic areas is growing rapidly.
Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class (Figure 1). It
is a cyclic heptapeptide which belongs to the class of the arginin-glycin-aspartat (RGD)
mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the
third inhibitor of GP IIb/IIIa that has found broad acceptance and has been approved by FDA
in 1998
Herein, we wish to report the new approach for the synthesis of an API antiplatelet drug
using Solid Phase Peptide Synthesis (SPPS) and suitable coupling reagents. The structure of
compounds was confirmed based on the HR-MS (ESI) data. The details about synthetic
approach and structure of product will be further discussed in the conference..
